{"id":29906,"date":"2025-06-18T18:32:07","date_gmt":"2025-06-18T18:32:07","guid":{"rendered":"https:\/\/medexperts.pro\/?p=29906"},"modified":"2025-06-18T19:27:00","modified_gmt":"2025-06-18T19:27:00","slug":"regulators-approve-lenacapavir-for-h-i-v-prevention","status":"publish","type":"post","link":"https:\/\/medexperts.pro\/?p=29906","title":{"rendered":"Regulators Approve Lenacapavir for H.I.V. Prevention"},"content":{"rendered":"
<\/div>\n

The drug could change the course of the AIDS epidemic. But the Trump administration has gutted the programs that might have paid for it in low-income countries.<\/p>\n

\n
\n
\n

The Food and Drug Administration on Wednesday approved a twice-yearly injection that provided a near-perfect shield against H.I.V. infection in clinical trials.<\/p>\n

The approval is among the most anticipated developments in the prevention of H.I.V. But it arrives during deep cuts to global health programs that were expected to purchase and distribute the drug in low-income countries.<\/p>\n

To what extent the drug, called lenacapavir, can now be rolled out is uncertain.<\/p>\n

\u201cWe\u2019re on the precipice of now being able to deliver the greatest prevention option we\u2019ve had in 44 years of this epidemic,\u201d said Mitchell Warren, executive director of the international H.I.V. prevention organization AVAC.<\/p>\n

\u201cAnd it\u2019s as if that opportunity is being snatched out of our hands by the policies of the last five months,\u201d he said.<\/p>\n<\/div>\n<\/div>\n

<\/div>\n
\n
\n

With much less money available, governments abroad may instead choose to prioritize treatment of the infected.<\/p>\n

\u201cWe were so excited about the possibilities,\u201d said Dr. Linda-Gail Bekker, who led a clinical trial of the drug. \u201cI don\u2019t think any of us envisaged this year going quite the way it has.\u201d<\/p>\n

\n
\n
<\/div>\n
\n
\n
\n

We are having trouble retrieving the article content.<\/p>\n

Please enable JavaScript in your browser settings.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into<\/a>\u00a0your Times account, or\u00a0subscribe<\/a>\u00a0for all of The Times.<\/p>\n

\n<\/div>\n
\n
\n

Thank you for your patience while we verify access.<\/p>\n

Already a subscriber?\u00a0Log in<\/a>.<\/p>\n

Want all of The Times?\u00a0Subscribe<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

The drug could change the course of the AIDS epidemic. But the Trump administration has gutted the programs that might have paid for it in low-income countries.The Food and Drug Administration on Wednesday approved a twice-yearly injection that provided a near-perfect shield against H.I.V. infection in clinical trials.The approval is among the most anticipated developments in the prevention of H.I.V. But it arrives during deep cuts to global health programs that were expected to purchase and distribute the drug in low-income countries.To what extent the drug, called lenacapavir, can now be rolled out is uncertain.\u201cWe\u2019re on the precipice of now being able to deliver the greatest prevention option we\u2019ve had in 44 years of this epidemic,\u201d said Mitchell Warren, executive director of the international H.I.V. prevention organization AVAC.\u201cAnd it\u2019s as if that opportunity is being snatched out of our hands by the policies of the last five months,\u201d he said.With much less money available, governments abroad may instead choose to prioritize treatment of the infected.\u201cWe were so excited about the possibilities,\u201d said Dr. Linda-Gail Bekker, who led a clinical trial of the drug. \u201cI don\u2019t think any of us envisaged this year going quite the way it has.\u201dWe are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into\u00a0your Times account, or\u00a0subscribe\u00a0for all of The Times.Thank you for your patience while we verify access.Already a subscriber?\u00a0Log in.Want all of The Times?\u00a0Subscribe.<\/p>\n","protected":false},"author":1,"featured_media":29908,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-29906","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lifestyle"],"_links":{"self":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/29906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=29906"}],"version-history":[{"count":2,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/29906\/revisions"}],"predecessor-version":[{"id":29909,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/29906\/revisions\/29909"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/media\/29908"}],"wp:attachment":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=29906"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=29906"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=29906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}